Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Akiyuki U"'
Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis
Autor:
Daiki Tokuyasu, Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Takamichi Sugimoto, Kei Ishizuchi, Munenori Oyama, Manato Yasuda, Hiroyuki Akamine, Yosuke Onishi, Yasushi Suzuki, Naoki Kawaguchi, Naoya Minami, Takashi Kimura, Masanori P. Takahashi, Hiroyuki Murai, Kimiaki Utsugisawa
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 11, Iss 5, Pp 1338-1346 (2024)
Abstract Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials an
Externí odkaz:
https://doaj.org/article/4435d7c8136845bebdde0611ea441e42
Autor:
Akiyuki Uzawa, Shigeaki Suzuki, Satoshi Kuwabara, Hiroyuki Akamine, Yosuke Onishi, Manato Yasuda, Yukiko Ozawa, Naoki Kawaguchi, Tomoya Kubota, Masanori P. Takahashi, Yasushi Suzuki, Genya Watanabe, Takashi Kimura, Takamichi Sugimoto, Makoto Samukawa, Naoya Minami, Masayuki Masuda, Shingo Konno, Yuriko Nagane, Kimiaki Utsugisawa
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Background Non-motor symptoms in myasthenia gravis (MG) are rarely confirmed. Although there are some small cohort studies, a large-systemic survey has not yet been performed. Methods We investigated the incidence and clinical characteristic
Externí odkaz:
https://doaj.org/article/baad5cedccef46fb912d7e8a25ebf57a
Autor:
Hideo Handa, Atsuhiko Sugiyama, Tadashi Kaname, Yoko Shigemoto, Noriko Sato, Shigeki Hirano, Yuki Nakagawa, Akiyuki Uzawa, Akiyo Aotsuka, Satoshi Kuwabara
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Background Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is a rare genetic disorder characterized by progressive cognitive decline and myoclonic epilepsy, caused by pathogenic variants of SERPINI1. We reported a case of g
Externí odkaz:
https://doaj.org/article/8a473ae3b90b45d0b32ce7ad40dfc6e7
Autor:
Hiroki Masuda, Masahiro Mori, Shigeki Hirano, Akiyuki Uzawa, Tomohiko Uchida, Mayumi Muto, Ryohei Ohtani, Reiji Aoki, Yoshiyuki Hirano, Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI), Satoshi Kuwabara
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract We aimed to compare longitudinal brain atrophy in patients with neuromyelitis optica spectrum disorder (NMOSD) with healthy controls (HCs). The atrophy rate in patients with anti-aquaporin-4 antibody-positive NMOSD (AQP4 + NMOSD) was compare
Externí odkaz:
https://doaj.org/article/d4e69a73ba97431aa09c443cd37a3941
Autor:
Hiroki Masuda, Masahiro Mori, Akiyuki Uzawa, Tomohiko Uchida, Mayumi Muto, Ryohei Ohtani, Reiji Aoki, Satoshi Kuwabara
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Lymphatic drainage in the central nervous system is regulated by meningeal lymphatic vasculature, and recurrent neuroinflammation alters lymphatic vessel remodeling. Patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum d
Externí odkaz:
https://doaj.org/article/e5008498960642a48fbdcea2dcd6858b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Takaki Hiwasa, Hao Wang, Ken-ichiro Goto, Seiichiro Mine, Toshio Machida, Eiichi Kobayashi, Yoichi Yoshida, Akihiko Adachi, Tomoo Matsutani, Mizuki Sata, Kazumasa Yamagishi, Hiroyasu Iso, Norie Sawada, Shoichiro Tsugane, Mitoshi Kunimatsu, Ikuo Kamitsukasa, Masahiro Mori, Kazuo Sugimoto, Akiyuki Uzawa, Mayumi Muto, Satoshi Kuwabara, Yoshio Kobayashi, Mikiko Ohno, Eiichiro Nishi, Akiko Hattori, Masashi Yamamoto, Yoshiro Maezawa, Kazuki Kobayashi, Ryoichi Ishibashi, Minoru Takemoto, Koutaro Yokote, Hirotaka Takizawa, Takashi Kishimoto, Kazuyuki Matsushita, Sohei Kobayashi, Fumio Nomura, Takahiro Arasawa, Akiko Kagaya, Tetsuro Maruyama, Hisahiro Matsubara, Minako Tomiita, Shinsaku Hamanaka, Yushi Imai, Tomoo Nakagawa, Naoya Kato, Jiro Terada, Takuma Matsumura, Yusuke Katsumata, Akira Naito, Nobuhiro Tanabe, Seiichiro Sakao, Koichiro Tatsumi, Masaaki Ito, Fumiaki Shiratori, Makoto Sumazaki, Satoshi Yajima, Hideaki Shimada, Mikako Shirouzu, Shigeyuki Yokoyama, Takashi Kudo, Hirofumi Doi, Katsuro Iwase, Hiromi Ashino, Shu-Yang Li, Masaaki Kubota, Go Tomiyoshi, Natsuko Shinmen, Rika Nakamura, Hideyuki Kuroda, Yasuo Iwadate
Publikováno v:
BMC Medicine, Vol 19, Iss 1, Pp 1-25 (2021)
Abstract Background Acute ischemic stroke (AIS) is a serious cause of mortality and disability. AIS is a serious cause of mortality and disability. Early diagnosis of atherosclerosis, which is the major cause of AIS, allows therapeutic intervention b
Externí odkaz:
https://doaj.org/article/9a2b8131969246478354b0215266296a
Publikováno v:
In Journal of the Neurological Sciences 15 October 2017 381 Supplement:792-793
Autor:
Tomihiro Imai, Shigeaki Suzuki, Yuriko Nagane, Akiyuki Uzawa, Hiroyuki Murai, Kimiaki Utsugisawa
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
Treatment with oral corticosteroids at high doses with an escalation and de-escalation schedule is effective against myasthena gravis (MG). In fact, the use of corticosteroids has led to a reduction in mortality to below 10% after the 1960s. However,
Externí odkaz:
https://doaj.org/article/32b16c3ef9a74070ae0502f2d833d34f
Autor:
Munenori Oyama, Kensuke Okada, Masayuki Masuda, Yuko Shimizu, Kazumasa Yokoyama, Akiyuki Uzawa, Naoki Kawaguchi, Ryotaro Ikeguchi, Yasunobu Hoshino, Taku Hatano, Yukiko Ozawa, Jin Nakahara, Hitoshi Aizawa, Kazuo Kitagawa, Nobutaka Hattori, Satoshi Kuwabara, Hiroyuki Murai, Shigeaki Suzuki
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 13 (2020)
Background: Eculizumab is a humanized monoclonal antibody that targets complement protein C5 and inhibits terminal complement-mediated damage at the neuromuscular junction. Recently, the REGAIN study showed that eculizumab was effective and well tole
Externí odkaz:
https://doaj.org/article/81fb81d66156442cb9f4fe3e8f53dd7a